Herbert Loong: Regulatory processes for novel oncology therapeutics and cellular therapies at APODDC forum
Herbert Loong shared a post on X:
”We welcomed Ke Liu, former Chief of Oncology of CBER of the U.S. FDA, FDA Oncology to share his personal experiences of regulatory processes for novel oncology therapeutics and cellular therapies. Very insightful discussions of these important topics.”
Source: Herbert Loong/X
Herbert Loong is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK), with additional roles as Deputy Medical Director of the Phase 1 Clinical Trials Centre and founder of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. Dr. Loong has co-founded key organizations like the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC). His involvement in international oncology bodies, including ASCO and IASLC, underscores his commitment to advancing cancer research and treatment on a global scale.
